Evidence map›Paper›PMID 38864416›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Assessment of brain-derived extracellular vesicle enrichment for blood biomarker analysis in age-related neurodegenerative diseases: An international overview.

AmanPreet Badhwar, Yael Hirschberg, Natalia Valle-Tamayo, M Florencia Iulita, Chinedu T Udeh-Momoh, Anna Matton, Rawan M Tarawneh, Robert A Rissman, Aurélie Ledreux, Charisse N Winston and 2 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

AmanPreet BadhwarDépartement de pharmacologie et physiologie, Institut de Génie Biomédical, Faculté de Médecine, Université de Montréal, Montréal, Quebec, Canada.
Yael HirschbergCentre for Proteomics, University of Antwerp, Antwerp, Belgium.
Natalia Valle-TamayoSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Calle San Quintí, Barcelona, Spain.
M Florencia IulitaSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Calle San Quintí, Barcelona, Spain.
Chinedu T Udeh-MomohAgeing Epidemiology research unit, School of Public Health, Imperial College London, London, UK.
Anna MattonAgeing Epidemiology research unit, School of Public Health, Imperial College London, London, UK.
Rawan M TarawnehDepartment of Neurology, Center for Memory and Aging, University of New Mexico, Albuquerque, New Mexico, USA.
Robert A RissmanVA San Diego Healthcare System, San Diego, California, USA.
Aurélie LedreuxDepartment of Neurosurgery, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Charisse N WinstonDepartment of Physiology and Neuroscience, Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, California, USA.
Arsalan S HaqqaniNational Research Council Canada, Ottawa, Ontario, Canada.
Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment: Biofluid Based Biomarkers Professional Interest Area‐Exosome Working Group (ISTAART‐BBB‐PIA‐EWG)

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAMES B BREWER · 2019 to 2026
$34.9M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
A Blood Test for Screening Into Alzheimer's Prevention TrialsR01AG058252 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E, RISSMAN, ROBERT · 2017 to 2021
$3.2M
Scientific CoreP20AG068077 · NIA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ADAIR, JOHN CHALMERS · 2020 to 2022
$3.1M
Exosome biology in Alzheimer's disease and concussion.R01AG071228 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER, LEDREUX, AURELIE · 2021 to 2025
$3.1M
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down SyndromeRF1AG073979 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RAFII, MICHAEL S, RISSMAN, ROBERT · 2021 to 2022
$2.6M
Elucidating the Role of Endothelial Dysfunction in Alzheimer Disease: Towards A New Data-Driven Disease ModelRF1AG083744 · NIA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI TARAWNEH, RAWAN · 2023 to 2023
$2.1M
Impact of TBI and Cognitive Decline on Alzheimer's Disease Brain-Derived Exosome CargoRF1AG079303 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RISBROUGH, VICTORIA B, RISSMAN, ROBERT · 2023 to 2023
$1.9M
Noradrenergic dysfunction in Down SyndromeRF1AG070153 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI LEDREUX, AURÉLIE · 2020 to 2020
$1.8M
UCSD Leading the Advancement of Underrepresented Neuroscientists for Change (LAUNCH) Faculty Development ProgramR25NS117367 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victoria B Risbrough, Joann Trejo · 2020 to 2026
$1.6M
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down SyndromeR01AG073979 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAFII, MICHAEL S, RISSMAN, ROBERT · 2024 to 2025
$1.2M
Alzheimer’s Disease Biomarker for Diagnosis and PrognosisR21AG067755 · NIA · OHIO STATE UNIVERSITY · PI AMER, AMAL O, TARAWNEH, RAWAN · 2020 to 2021
$417k
Flemish Institute for Technological ResearchFondation CourtoisFonds de Recherche Québec-SantéNIA NIH HHS AG058252NIA NIH HHS AG073979NIA NIH HHS AG079303NIA NIH HHS K99 AG070390NIA NIH HHS K99AG070390-01NIA NIH HHS P20 AG068077NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG058252NIA NIH HHS R01 AG071228NIA NIH HHS R21 AG067755NIA NIH HHS RF1 AG070153NIA NIH HHS RF1 AG073979NIA NIH HHS RF1 AG079303NIA NIH HHS RF1 AG083744NIH HHS AG067755NIH HHS AG068077NIH HHS AG070153NIH HHS AG071228NINDS NIH HHS R25 NS117367UNM Grand Challenges Initiative
6 · The paper itself

Abstract

introductionBrain-derived extracellular vesicles (BEVs) in blood allows for minimally-invasive investigations of central nervous system (CNS) -specific markers of age-related neurodegenerative diseases (NDDs). Polymer-based EV- and immunoprecipitation (IP)-based BEV-enrichment protocols from blood have gained popularity. We systematically investigated protocol consistency across studies, and determined CNS-specificity of proteins associated with these protocols.

methodsNDD articles investigating BEVs in blood using polymer-based and/or IP-based BEV enrichment protocols were systematically identified, and protocols compared. Proteins used for BEV-enrichment and/or post-enrichment were assessed for CNS- and brain-cell-type-specificity, extracellular domains (ECD+), and presence in EV-databases.

resultsA total of 82.1% of studies used polymer-based (ExoQuick) EV-enrichment, and 92.3% used L1CAM for IP-based BEV-enrichment. Centrifugation times differed across studies. A total of 26.8% of 82 proteins systematically identified were CNS-specific: 50% ECD+, 77.3% were listed in EV-databases.

conclusionsWe identified protocol steps requiring standardization, and recommend additional CNS-specific proteins that can be used for BEV-enrichment or as BEV-biomarkers. HIGHLIGHTS: Across NDDs, we identified protocols commonly used for EV/BEV enrichment from blood. We identified protocol steps showing variability that require harmonization. We assessed CNS-specificity of proteins used for BEV-enrichment or found in BEV cargo. CNS-specific EV proteins with ECD+ or without were identified. We recommend evaluation of blood-BEV enrichment using these additional ECD+ proteins.

Indexed as

BiomarkersBrainExtracellular VesiclesNeurodegenerative DiseasesHumansBiomarkersage‐related neurodegenerative diseasesAlzheimer's diseasebiofluid based biomarkersbloodbrain‐derived extracellular vesiclesexosomesimmunoprecipitation‐based enrichmentmicrovesiclesnovel biomarkersprotocol variability

Identifiers

PMID38864416
PMCPMC11247682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.